Your browser doesn't support javascript.
loading
A streamlined CRISPR workflow to introduce mutations and generate isogenic iPSCs for modeling amyotrophic lateral sclerosis.
Deneault, Eric; Chaineau, Mathilde; Nicouleau, Michael; Castellanos Montiel, Maria José; Franco Flores, Anna Kristyna; Haghi, Ghazal; Chen, Carol X-Q; Abdian, Narges; Shlaifer, Irina; Beitel, Lenore K; Durcan, Thomas M.
Affiliation
  • Deneault E; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Chaineau M; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Nicouleau M; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Castellanos Montiel MJ; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Franco Flores AK; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Haghi G; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Chen CX; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Abdian N; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Shlaifer I; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Beitel LK; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.
  • Durcan TM; The Neuro's Early Drug Discovery Unit (EDDU), McGill University, 3801 University Street, Montreal, Quebec H3A 2B4, Canada. Electronic address: thomas.durcan@mcgill.ca.
Methods ; 203: 297-310, 2022 07.
Article in En | MEDLINE | ID: mdl-34500068
ABSTRACT
Amyotrophic lateral sclerosis (ALS) represents a complex neurodegenerative disorder with significant genetic heterogeneity. To date, both the genetic etiology and the underlying molecular mechanisms driving this disease remain poorly understood, although in recent years several studies have highlighted a number of genetic mutations causative for ALS. With these mutations pointing to potential pathways that may be affected within individuals with ALS, having the ability to generate human neurons and other disease relevant cells containing these mutations becomes even more critical if new therapies are to emerge. Recent developments with the advent of induced pluripotent stem cells (iPSCs) and clustered regularly interspaced short palindromic repeats (CRISPR) gene editing fields gave us the tools to introduce or correct a specific mutation at any site within the genome of an iPSC, and thus model the specific contribution of risk mutations. In this study we describe a rapid and efficient way to either introduce a mutation into a control line, or to correct an allele-specific mutation, generating an isogenic control line from patient-derived iPSCs with a given mutation. The mutations introduced were the G94A (also known as G93A) mutation into SOD1 or H517Q into FUS, and the mutation corrected was a patient iPSC line with I114T mutation in SOD1. A combination of small molecules and growth factors were used to guide a stepwise differentiation of the edited cells into motor neurons in order to demonstrate that disease-relevant cells could be generated for downstream applications. Through a combination of iPSCs and CRISPR editing, the cells generated here will provide fundamental insights into the molecular mechanisms underlying neuron degeneration in ALS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induced Pluripotent Stem Cells / Amyotrophic Lateral Sclerosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: Methods Journal subject: BIOQUIMICA Year: 2022 Document type: Article Affiliation country: Canada Country of publication: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Induced Pluripotent Stem Cells / Amyotrophic Lateral Sclerosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: Methods Journal subject: BIOQUIMICA Year: 2022 Document type: Article Affiliation country: Canada Country of publication: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA